India’s drugmakers are warning that a government directive restricting surplus ammonia supply to fertiliser firms could trigger a raw material crunch for pharmaceuticals. Since ammonia is a key input for API production, limited alternative sourcing may disrupt manufacturing, raise the risk of medicine shortages, and hit export commitments.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
